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SUMMARY
Although substantial progress has been made in the struggle against cancer, new anti-tumor
strategies are still needed. A candidate strategy is the use of a so-called 'suicide gene, in
combination with a prodrug. To this end, the herpes simplex virus thymidine kinase (I{SV-
tk)/ganciclovir (GCV) suicide gene/prodrug system has been extensively studied over the past
fifteen years in preclinical and clinical settings (l).
After transfection with the HSV{k suicide gene, cells can conveft the non-toxic prodrug GCV into
toric metabolites, resulting in selective elimination of these cells. However, high percentages of
transfected cells are not mandatory for complete eradication of a tumor in vivo. TransÍècted tumor
cells appear to be capable ofinducing the death ofneighboring untransfected cells. This cell kill is
called the "bystander eÍïect" (BE). In various models, both in vitro and, in vivo studies have shown,
that a transfèction percentage of as little as l0oÁ was sufficient to kill an entire tumor population.
However, despite these promising results, the anti-tumor eÍïects obtained in clinical trials remain
poor. One of the main problems in these trials is to obtain sufficient transfection percentages.
Transfection percentages far below the l0% are common. Therefbre, research is still focusing on
improving the transfection efficiency via the development of new vectors and tumor targeting
strategies.
For this purpose, it would be parlicularly helpful to assess the effectiveness of HSV-tk/GCV gene
therapy in a non-invasive manner. One of the methods under evaluation for this purpose is the
imaging of HSV-tk/GCV gene therapy with positron emission tomography (pET) (2,lal). In
contrast to unmodified cells, cells transÍècted with the HSV-tk gene can phosphorylate GCV
labeled with a positron-emitting isotope. The trapping of the PET tracer can be visualized with a
PET camera and in this manner transfection efÍiciencies can be monitored.
The aim of this thesis was to evaluate factors that could improve the clinical outcome of HSV-
tk/GCV gene therapy. In addition, we evaluated the radioactively labeled GCV analog, 9-t(3-
['EF]fluoro-l-hydroxy-2-propoxy)methyl]guanine ([r8F]FHPG) as a PET tracer for monitonns
HSV-tk/GCV suicide gene therapy.
ln chapter 1, an overview is given of the current knowledge on the BE in vitro and in vivo. In
addition, theories conceming its mechanisms and possible approaches to augment this effect are
discussed. Especially the role of gap junctional intercellular communication (GJIC) is emphasized.
In the second part of this chapter, an overview of clinical trials using suicide gene therapy is
oresented.
Currently, research is especially focusing on enhancement of transfection efficiencies. In this
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different molecular cell characteristics on the HSV-tk/GCV induced BE, rvas studied. In chapter 4,
the potential of cornbining HSV-tklGCV gene therapy r.vitl.r standard chemotherapy was
investigated.
ln chapter 2, the influence of p53 mutations on the HSV-Ik/GCV inducecl BE, r,vas studied in a
human ovarian carcinoma cell line transÍècted rvith an ernpty vector (A2780/cmr') or a Iector
containing a p53 hotspot mutation at codon 175 (A2780/m175) or 248 (A27801m248). The p53
ptotein is tnutated in 50"Á of all human tumors and plays a key role in the induction of cell cycle
aruest and apoptosis. Moreover, p53 mutations are associated r.vith the occurrence ol
chemoresistance. Our results show that in our model, p53 rnutations led also to resistance to GCV.
Furthermore, it was shor.vn that the two tested hotspot n.rutations had a difÍerent efÍèct on the HSV-
tk/GCV induced BE. The BE in A2780/rn248 was cornparable to the BE in A2780/crnv. On the
other hand" in A2780Án175, an increased survival, instead of an increased cell ki l l  rvas found. The
diÍ1èrences could not be attributecl to difÍèrences ir.r expression of the drug etÏlux pruxps. MRP4
and MRP5, or the expression of the gap junction protein, Cx43. However. modulation of the GJIC
with l8-u-glycynhetinic acid (AGA) significantly decreased the BE in all cell l ines, suggesting a
role fbr GJIC in the I{SV-IVGCV induced BE in this cell l ine model.
Chapter 3 shows the consequences of ín viÍro acquired chemoresistance on the t{SV-tk/GCV
induced BE in an isogenic human small cell lung cancer cell line model. GCV sensitivity rvas
diminished in all chemoresistarlt sublines. Additionally, the HSV{k/GCV induced BE was
increased in the subline resistant fot adriarnycin, whereas the BE was decreased in the cisplatin-
resistant cell line. The differences in BE betu'een the chemoresistant and the parental cell lines
could not be attributed to MRP4/5 or Cx43 expression. In addition, in none of the cell lines the BE
could be inhibited by blocking GJIC with AGA. Thus, our results show that chemoresistance
influences the HSV-tk/GCV induced BE. The underlying mechanisms still har,e to be clarified.
In chapter 4, the possibilities are explored to enhance the therapeutic outcome of Ë1SV+k/GCV
suicide gene therapy by combining it with standard chemotherapy. The inÍluence of HSV-tk
transfèction on chemotherapeutic drug sensitivity rvas tested in a rat gliorna cell line model. The
rat gliorna cell line was transtècted rvith either an HSV-tk expressing plasmid, or a HSV-tk
expressing retroviral vector. Four chemotherapeutic drugs were tested with difïerent mechanisms
of action: adriamycin. cisplatin, 5-flr.rorouracil, and methotrexate. In both HSV-tk transÍècted cell
lines, an increase in sensitivity to cisplatin and a decl'ease in sensitir,'ity to adriamycin and
methotrexate was shor.vn. No diÍferences were found in sensitivity to 5-fluorouracil. Experiments
combining GCV with one of the chemotherapeutic drugs were performecl in the plasmid
transÍècted cell line. In this model, transfection with HSV-tk led to an increased cell kill after
combined treatment with GCV and either adriamycin, cisplatin, or S-fluorouracil. However, the
combination of GCV with methotrexate led to a decreased cell kill, relative to treatment r.vith GCV
or methotrexate alone. These results suggest that patients could benet'it from the combination of
HSV-tk/GCV gene therapy and chemotherapy, although the simultaneous use of methotrexate with
HSV-tk/GCV gene therapy should be discouraged.
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Arrother potential irnprovement of HSV-tk/GCV gene therapy in clinical trials would be the
possibility to establish non-invasively to u'hat extent HSV-tk gene transfer was achieved.
Additionally, it is a major challenge to detenline the kinetics of the HSV-tk expression and to
monitor GCV kinetics. The development of non-invasive imaging techniques would therefore be
very valuable. For this purpose, PET is curreutly under investigation.
In this thesis, the radioactive labeled compound IrsF]FHPG rvirs tested for its applicabil ity as PET
tracer for monitoring HSV-tkJGCV gene therapy.
ln chapter 5, the relationship between 1r8f1FHtC accumulation and HSV-tk expression was
studied in HSV-tk expressing tumor-bearing rats with PET and autoradiography. ;rsnlfHeC
distribution closely corresponded rvith HSV-tk immunohistochernical staining. Two different
ar.ralysis metl.rods were used to quantif' the Ir8F]l"HPG uptake: region of interest (ROl) analysis ol
tracer uptake ? hours p.i. and Patlak graphical analysis. For both methods, the [I8F]FHPG PET
signal correlated rvell with the fi'action of HSV-tk expressing tumor cells implanted, but shou'ed a
plateau when plotted against HSV-tk protein levels. This might be due to rate l imiting [ '8F]FHPG
mer.r.rbrane h'ansport.
In chapter 6, the inÍ-luence of membrane transpoft on 1'8FIFIIPG uptake in IISV-tk expressing
cells was further explored. Our results demonstrate that II8F]FHPG transporl can be blocked
conrpletely by the addition of adenine, both rr viÍr'o as well as in vivo. Adenine is a substrate of the
purine nucleobase transporter. Therefore it is rnost likely that the intracellular uptake of
[|SF]FHPG occurs via this tratrspofter as rvell. In general, GCV is transported via nucleoside
transporters. Our results also slrowed that [rnF]FHPG transport in intact cells is not completely
blocked after addition of GCV, whereas 1'tflnHeC phosphorylation in cell lysates is. This
indicates that in the intact cells, intracellular GCV concentrations rvere too low to inhibit the HSV-
tk enzyme courpletely, suggesting that transport of GCV into the rat glioma cell is a slow process.
For visualization with PET usr"rally PET tracers with shorl half-lives are used. Subsequently,
visualization of gene transfection and GCV kinetics with PET tracers strongly depends on
membrane transpoft of the tracer. When GCV is used íbr therapeutic purposes, GCV treatment
depends less on membrane trarlsporl, since enouglr tinte is available Íbr the intracellular uptake of
the drug. Ilowever, for monitoring drug kinetics and predictin-u therapy outcome with PET, a close
resemblance between drug and PET tracer is necessary. Both, chapter 5 and chapter 6, lead to the
conclusion that II8F]FIIPG does not mimic GCV transport sufÍiciently. Therefore, 1'nnlRHlG
seeurs not a suitable tracer for monitoring GCV kinetics and predicting HSV-Ik/GCV gene therapy
outcome.
CONC LASIONS AND PE RSPECTIVES
In this thesis, w,e have investieated several Íactors that could affect the outcorne of HSV{k/GCV
suicide gene therapy.
Our results showed that, p53 mutations and in vitro acquired chemoresistance can both increase or
decrease the BE, depending on the type of mutation or drug resistance. Although we could not
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CONCLUSIONS AND PERSPECTIVES
elucidate the exact underlying mechanism, it is important to know that these factors can inÍIuence
the RE and thus the clinical result.
One of the characteristics of patients in clirrical trials is their pretreatment with an other anti-tumor
therapy before entering a clinical gene therapy trial. lf this treatlnent has induced chemoresistance,
this could result in a poor clinical response to the subsequent HSV-Ik/GCV gene therapy as well
(chapter 3). ln addition,50oÁ of all human tumors contain a p53 mutation. In our cell l ine model
(chapter 2) it was shown that a hotspot mutation at codon 175 could induce an increased tumor
sut-v-ival compared to the fumor survival expected. The tiequency of p53 mutations might therefore
contribute to the disappointing results as well.
In the fufure, treatment and anti-tumor efÍècts might be improved by preselection of patients Íbr
IISV-k/GCV gene therapy on basis of their treatment history or their p53 status. However, more
research has to be done in other models to r.erily and establish our results. It would for example be
interesting to trausfect other human tumor cell lines with the HSV-tk gene and evaluate GCV
serrsitivify and BE in viÍr'o and in vívo, in order to establish whether these parameters depencl on
the chosen model.
Another interesting observ'ation is the significant BE obtained when rat glioma cell lines r.vere
mixed with human tumor cell lines. This offers possibilities to perform suicide gene therapy using
transfècted cells as gene delivery vehicles. The advantage of this approach would be the possibility
to control and select the cells Íbr ÍISV-tk expression beÍbre intra-tumoral injection into patients.
Also cells could be selected according to certain cell characteristics Íbr which is known that they
are of benefit for HSV-tk/GCV suicide gene therapy. Selection of cells r.vith a high level of GJIC,
would Íbr example increase the BE, subsequently leading to an increased clinical outcome.
An alternative way to augment the anti-tumor eÍïect of HSV-IVGCV gene therapy is by
combining it with chernotherapy. Our results (chapter 4) showed that this approach could enhance
tumor cell kill in the HSV-tk transfected cells, especially if HSV-tk/GCV gene therapy was
combined with the topoisomerase inhibitor adriamycin or the DNA-bincling agent cisplatin.
Combined modality treatment is thereÍbre a promisir.rg anti-tumor approach. flowever, care has to
be taken which combination is used, as a combination with methotrexate led to a strong
antagonistic elfect with even an increased survival of the tumor cells in our model, as compared to
single rnodality treatnent. To assess the scope of the combined treatment strategy, the eÍÏèct of
cornbining HSV-tk/GCV gene therapy and chen.rotherapy with ditïerent topoisornerase inhibitors
or DNA binding agents still has to be confirmed ir.r other tumor rnodels as well. Additionally,
fur1her esearch has to be performed to establish whether combined modality treatment also leads
to an increased tumor cell kill in patients. An interesting approach would be to evaluate this
combined strategy in different cell lines with different topoisomerase inhibitors or DNA binding
agents.
Finally, we have evaluated the radiolabeled compound [r8F]FHPG as new PET tracer for the
visualization of ItSV-tk/GCV gene therapy. It was demonstrated before that 1r8F1FHPG r.r'as
capable of detecting HSV-tk gene expression (141). However, our studies showed that only low
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and intermediate HSV-tk protein expression correlated well with the IrEF']FHPG uptake in the
tumor, most probably due to rate lirniting 1r8n1nUeC ftansport (chapter 5). In addition,
Ii8F]FHPG uptake into the cell occurs via a different transporler than GCV uptake (chapter 6). A
method that can non-invasively measure GCV kinetics could potentially be used to discriminate
between responders and non-responders at the onset of GCV treatment. For evaluation of drug
kinetics a close similarity between drug and PET tracer is essential. ThereÍbre, we conclude that
[rst']FHpG does not mimic GCV enough to be a suitable tracer for measuring GCV kinetics in
HSV-tk/GCV gene therapy.
In the future a new tracer has to be developed which resembles GCV more precisely and can
predict GCV kinetics, and thus the sensitivity of tumor cells for this therapy, more accurately.
Various tracers are yet under investigation. However, for none of them has yet been established
that both HSV-tk expression as GCV kinetics can be monitored precisely.
Obviously, the clinical outcome of suicide gene therapy depends on lnany factors. As Íbr HSV-
tk/GCV suicide gene lherapy, the factors we evaluated might be important for other suicide
gene/prodrug combinations as well. We therefore think that although enhancement of transfection
percentages is of great importance for the success of suicide gene therapy, research should be
directed on identifring other contributing factors as well. In addition, our results show that there
are still various ways to improve the clinical outcome of HSV-tIíGCV gene therapy. For that
reason, HSV-tk/GCV suicide gene therapy is still a promising strategy for anti-tumor therapy.
SAMEIvv.
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